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Repaglinide has the half life of 1 hour, and bioavailability in the body is 56% due to ﬁrst-pass metabolism. The total daily dose
of Repaglinide is 16mg (e.g., 4mg four times daily depending on meal patterns); hence, it required frequent dosing. Transdermal
patch of Repaglinide was prepared to sustain the release and improve bioavailability of drug and patient compliance. Diﬀerent
formulations were prepared by varying the grades of HPMC and concentration of PVP K30 by solvent casting method. The
prepared formulations were evaluated for various parameters like thickness, tensile strength, folding endurance, % elongation, %
moisture content, % moisture uptake, % drug content, in vitro drug release, in vitro permeation, and drug excipient compatibility.
A3 2 full factorial design was applied to check the eﬀe c to fv a r y i n gt h eg r a d e so fH P M C( X1) and PVP concentration (X2)o n
the responses, that is, tensile strength, percentage drug released in 1hr (Q1), 9hr (Q9), and diﬀusion coeﬃcient as a dependent
variables. In vitro release data were ﬁtted to various models to ascertain kinetic of drug release. Regression analysis and analysis of
variance were performed for dependent variables. The results of the F2 statistics between factorial design batches and theoretical
proﬁle were used to select optimized batch. Batch F6 was considered optimum batch which contained HPMC K100 and PVP
(1.5%), showed release 92.343% up to 12hr, and was more similar to the theoretical predicted dissolution proﬁle (f2 = 69.187).
1.Introduction
Transdermal drug delivery system (TDDS) has been an
increased interest in the drug administration via the skin
for both local therapeutic eﬀects on diseased skin (topical
delivery) as well as for systemic delivery of drugs. The skin as
a site of drug delivery has a number of signiﬁcant advantages
over many other routes of drug administration, including
the ability to avoid problems of gastric irritation, pH and
emptying rate eﬀects, avoid hepatic ﬁrst-pass metabolism
thereby increasing the bioavailability of drug, reduce the risk
of systemic side eﬀects by minimizing plasma concentrations
compared to oral therapy, provide a sustained release of
drug at the site of application; rapid termination of therapy
by removal of the device or formulation, the reduction
of ﬂuctuations in plasma levels of drugs, and avoid pain
associated with injections. The transdermal delivery can also
eliminate pulsed entry into the systemic circulation, which
might often cause undesirable side eﬀects [1].
Diabetes mellitus is a major and growing health problem
worldwide and an important cause of prolonged ill health
and early death. It is a chronic metabolic disorder character-
ized by a high blood glucose concentration (hyperglycemia)
caused by insulin deﬁciency, and it is often combined
with insulin resistance [2]. Repaglinide is an oral blood-
glucose-lowering drug of the meglitinide class use to treat
NIDDM (noninsulin-dependent diabetes mellitus). It lowers
blood glucose by stimulating the release of insulin from
the pancreas. It has an extremely short half life of 1h. In
addition, the oral bioavailability of Repaglinide is low (56%)
due to extensive hepatic ﬁrst-pass eﬀect. Dosage frequency
of Repaglinide is 0.5 to 4mg in 3 to 4 times in a day. It
has melting point of 130-131◦C and mol. wt. 452.58 [3–6].
It belongs to class 2 drug. Repaglinide topical preparation
may be beneﬁcial to the patient since it reduce adverse
eﬀects and avoid the hepatic ﬁrst-pass metabolism. The need
for transdermal delivery of Repaglinide is further justiﬁed
due to the requirement of maintaining unﬂuctuating plasma
concentrations for eﬀective management of blood sugar for
long period in diabetic patients.
Thepurposeofthepresentworkwastodeveloptransder-
mal formulation of Repaglinide which increases the patient2 ISRN Pharmaceutics
compliance and also sustain the release of drug to increase
the bioavailability by using diﬀerent grades of HPMC and
PVP K30 as polymers.
2.MaterialsandMethods
2.1. Materials. Repaglinide was received as a gift sample
from Torrent Pharmaceutical Ltd., Gujarat, India. HPMC
K4M, HPMC K100, and HPMC E15 LV were purchased
from Yarrow Chem, Mumbai, India. PVP K30 was obtained
from SD ﬁne—Chem. Ltd, Mumbai. Polyethylene glycol 400
and propylene glycol were obtained from Merck Specialities
PrivateLtd.(Mumbai)andChemdyesCorporation(Ahmed-
abad, Gujarat) respectively. Cellulose acetate membrane
was obtained from Sartorius Biotech GmbH (Germany).
All other materials and chemicals used were of either
pharmaceutical or analytical grade.
2.2. Methods
2.2.1. Preparation of Transdermal Patch. Drug-loaded ma-
trix-type transdermal patches of Repaglinide were prepared
byusingsolventcastingmethod.Apetridishwithatotalarea
of 44.15cm2 was used. Polymers were accurately weighed
and dissolved in 10mL of water,methanol (1:1) solution
and kept aside to form clear solution. Drug was dissolved
in the above solution and mixed until clear solution was
obtained. Polyethylene glycol 400 (30%w/w of total poly-
mer) was used as plasticizer and propylene glycol (15%w/w
of total polymer) was used as permeation enhancer. The
resulted uniform solution was cast on the petri dish, which
was lubricated with glycerin and dried at room temperature
for 24h. An inverted funnel was placed over the petri dish to
prevent fast evaporation of the solvent. After 24h, the dried
patches were taken out and stored in a desiccator for further
studies [7].
2.2.2. Preliminary Screening. Preliminary study was carried
out to check eﬀect of various polymer combinations on
transdermal patch formulation. Composition of preliminary
trial batches P1 to P5 is shown in Table 1.
2.2.3. Optimization of Variables Using Full Factorial Design.
A3 2-randomized full factorial design was used in the present
study. In this design, 2 independent factors were evaluated,
each at 3 levels, and experimental trials were performed for
all 9 possible combinations. The diﬀerent grades of HPMC
(X1) and concentration of PVP K30% (X2) were chosen
as independent variables in 32 full factorial designs. Tensile
strength, cumulative % drug release at 1h (Q1), cumulative
% drug release at 9h (Q9), and diﬀusion coeﬃcient (n)w e r e
taken as dependent variables. The formulation layout for the
factorial design batches (F1 to F9) are shown in Table 2.
2.2.4. Evaluation Parameters of Transdermal Patch.
Folding Endurance [8]. A strip of speciﬁc area (2cm∗2cm)
was cut evenly and repeatedly folded at the same place till
it broke. The number of times the ﬁlm was folded at the
same place without breaking gave the value of the folding
endurance.
Tensile Strength [7]. The tensile strength of the patch was
evaluatedbyusingthetensiometer(Erectionandinstrumen-
tation, Ahmedabad). It consists of two load cell grips. The
lower one was ﬁxed and upper one was movable. Film strips
with dimensions of 2∗2cm were ﬁxed between these cell
grips, and force was gradually applied till the ﬁlm broke. The
tensilestrengthwastakendirectlyfromthedialreadinginkg.
Percentage Elongation Break Test [9]. The percentage elonga-
tion break was determined by noting the length just before
the break point, the percentage elongation was determined
from the below mentioned formula.
Elongation percentage =
 (L1 −L2)
L2
 
×100, (1)
where L1 is the ﬁnal length of each strip, and L2 is the initial
length of each strip.
Thickness [8]. Patch thickness was measured using digital
micrometer screw gauge at three diﬀerent places, and the
mean value was calculated.
Drug Content [1]. A speciﬁed area of patch (2cm∗2cm)was
dissolved in 100mL methanol and shaken continuously for
24h. Then the whole solution was ultrasonicated for 15min.
After ﬁltration, the drug was estimated spectrophotomet-
rically at wavelength of 281nm and determined the drug
content.
Percentage Moisture Content [8]. The prepared ﬁlms were
weighed individually and kept in a desiccator containing
fused calcium chloride at room temperature for 24h. After
24h, the ﬁlms were reweighed and determined the percent-
age moisture content from the below mentioned formula:
Percentage moisture content
=
  
Initial weight −Final weight
 
Final weight
 
×100.
(2)
PercentageMoistureUptake[8]. Theweighedﬁlmswerekept
in a desiccators at room temperature for 24h containing
saturatedsolutionofpotassiumchlorideinordertomaintain
84% RH. After 24h, the ﬁlms were reweighed and determine
the percentage moisture uptake from the below mentioned
formula:
Percentage moisture uptake
=
  
Final weight −Initial weight
 
Initial weight
 
×100.
(3)
In Vitro Drug Release Studies [1]. In Vitro drug release
studies were performed by using a Franz diﬀusion cell withISRN Pharmaceutics 3
Table 1: Preliminary trial batches.
Batch code Polymer Polymer proportion Solvent Plasticizer (30%w/w)∗
P1 PVA:PVP 1:1 Water PG
P2 HPMC K100M:PVP 1:1 Water PEG
P3 HPMC K4M:PVP 1:1 Water PEG
P4 EC:PVP 1:4 CHCl3 PG
P5 EC:HPMC K4M 3:7 Ethanol:DCM PEG
Each batch contains 4mg drug in 4cm2 area. ∗30%w/w of total polymer weight.
Table 2: Formulation and evaluation of 32 full factorial design batches.
Batch code X1( H P M Cg r a d e ) X2( %P V PK 3 0
concentration)
Y1 (tensile strength
kg/cm2) Y2( Q1)(%) Y3( Q9)(%) Y4( d i ﬀusion
coeﬃcient)
F1 HPMC E15 LV 0.5 0.38 9.780612 88.91582 1.043
F2 HPMC E15 LV 1 0.46 11.31122 90.59949 1.001
F3 HPMC E15 LV 1.5 0.63 12.22959 98.26531 0.983
F4 HPMC K100 0.5 0.45 13.30102 54.54082 0.665
F5 HPMC K100 1 0.58 13.91327 63.78827 0.746
F6 HPMC K100 1.5 0.92 18.96429 75.90561 0.641
F7 HPMC K4M 0.5 0.53 7.331633 48.52041 0.959
F8 HPMC K4M 1 0.84 8.862245 37.98469 0.656
F9 HPMC K4M 1.5 0.95 9.627551 57.70408 0.853
a receptor compartment capacity of 60mL. The cellulose
acetate membrane was used for the determination of drug
from the prepared transdermal matrix-type patches. The
cellulose acetate membrane having a pore size 0.45μ was
mounted between the donor and receptor compartment
of the diﬀusion cell. The prepared transdermal ﬁlm was
placed on the cellulose acetate membrane and covered with
aluminum foil. The receptor compartment of the diﬀusion
cell was ﬁlled with phosphate buﬀer pH 7.4. The whole
assembly was ﬁxed on a hot plate magnetic stirrer, and
the solution in the receptor compartment was constantly
and continuously stirred using magnetic beads, and the
temperature was maintained at 32±0.5◦C, because the
normal skin temperature of human is 32◦C. The samples
were withdrawn at diﬀerent time intervals and analyzed for
drugcontentspectrophotometrically.Thereceptorphasewas
replenishedwithanequalvolumeofphosphatebuﬀerateach
sample withdrawal.
InVitroPermeationStudy[10]. Aninvitropermeationstudy
was carried out by using Franz diﬀusion cell. Full thickness
abdominal skin of male Wistar rat weighing 200 to 250g
was used. Hair from the abdominal region was removed
carefully by using an electric clipper; the dermal side of the
skin was thoroughly cleaned with distilled water to remove
any adhering tissues or blood vessels, equilibrate for an
hour in phosphate buﬀer pH 7.4 before starting the exper-
iment, and was placed on a magnetic stirrer with a small
magnetic needle for uniform distribution of the diﬀusant.
The temperature of the cell was maintained at 32±0.5◦C
using a thermostatically controlled heater. The isolated rat
skin piece was mounted between the compartments of the
diﬀusion cell, with the epidermis facing upward into the
donor compartment. Sample volume of 5mL was removed
from the receptor compartment at regular intervals, and
an equal volume of fresh medium was replaced. Samples
were ﬁltered through watman ﬁlter and were analyzed
using Shimadzu UV 1800 double-beam spectrophotometer
(Shimadzu, Kyoto, Japan). Flux was determined directly as
the slope of the curve between the steady-state values of the
amount of drug permeated (mg∗cm2)v e r s u st i m ei nh o u r s
andpermeabilitycoeﬃcientwasdeducedbydividingtheﬂux
by the initial drug load (mg∗cm2).
2.2.5. Kinetic Modeling of Dissolution Data. The release
proﬁle of all batches were ﬁtted to various mathematical
models such as Zero order, First order, Higuchi [11], Hixon
and Crowell [12], and Korsmeyer et al. [13], to ascertain the
kinetic of drug release.
2.2.6. Comparison of Dissolution Proﬁles for Selection of
Optimum Batch. The similarity factor (f2)g i v e nb yS U P A C
guidelines for a modiﬁed release dosage form was used as
a basis to compare release proﬁles. The release proﬁles are
considered to be similar when f2 is between 50 and 100. The
r e l e a s ep r o ﬁ l eo fp r o d u c t sw e r ec o m p a r e du s i n ga nf2 which
is calculated from following formula:
f2 = 50 ×log
⎧
⎪ ⎨
⎪ ⎩
⎡
⎣1+
 
1
n
  n  
t=1
wt(Rt −Tt)
2
⎤
⎦
−0.5
×100
⎫
⎪ ⎬
⎪ ⎭
,
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Table 3: Results for preliminary trial batches.
Batch code Thickness (mm) Tensile strength (kg/cm2) % elongation Folding endurance CPR (%)
P1 0.12 20 22.5 82 101.26
P2 0.13 22 22.5 79 90.03
P3 0.15 20 17.5 76 75.89
P4 0.15 9 5 22 65.27
P5 0.20 8 5 20 62.49
Table 4: Evaluation parameters of factorial batches F1 to F9.
Sr. no. Batch
code
Folding
endurance
Tensile strength
(kg/cm2) (mean ±
S.D.)
% Elongation
(Mean ± S.D.)
Thickness (mm)
(mean ± S.D.)
%D r u gc o n t e n t
(mean ± S.D.) f2 value
1F 1 < 150 0.38 ±0.015 41.2 ±0.015 0.12 ±0.025 78.98 52.58
2F 2 < 150 0.46 ±0.012 38.8 ±0.014 0.15 ±0.062 78.941 49.97
3F 3 > 200 0.63 ±0.015 37.1 ±0.012 0.25 ±0.022 78.63 45.44
4F 4 > 200 0.45 ±0.014 40.2 ±0.013 0.22 ±0.012 77.851 31.38
5F 5 > 200 0.58 ±0.015 39.6 ±0.017 0.15 ±0.015 78.327 44.75
6F 6 > 200 0.92 ±0.017 35.8 ±0.012 0.17 ±0.013 77.956 69.18
7F 7 > 200 0.53 ±0.011 39.2 ±0.013 0.16 ±0.021 75.829 26.13
8F 8 > 200 0.84 ±0.017 28.9 ±0.015 0.13 ±0.018 74.683 23.09
9F 9 > 200 0.95 ±0.015 30.1 ±0.015 0.23 ±0.015 74.282 34.03
Values expressed as mean ± S.D, n = 3.
where n is the release time and Rt and Tt are the reference
(here this is the theoretical proﬁle of Repaglinide and test
value at time t [14].
2.2.7. Drug Excipients Compatibility Study. Fourier trans-
form infrared (FTIR) technique was used to study the phys-
ical and chemical interaction between drug and excipients.
FTIR spectrum of Repaglinide, HPMC K4M, HPMC K100,
HPMCE15LV,PVPK30,andaphysicalmixtureofRepaglin-
ide: HPMC (K100/K4M/E15 LV): PVP K30 was recorded
using KBr mixing method on FTIR (FTIR-1700, Shimadzu,
Kyoto, Japan). IR spectra are shown in Figures 7 and 8
3. Result andDiscussion
3.1. Preliminary Study. All the batches of transdermal patch
showed thickness variation range from 0.12 to 0.20mm as
shown in Table 3. High thickness of batch P4 and P5 was
found, it may be due to low solubility of ethyl cellulose in
solvent render uneven distribution of polymer layer. All the
batches of transdermal patch showed tensile strength and
% elongation in uniform range from 16 to 22 and 17.5 to
22.5, respectively, except batches P4 and P5 may be due to
poor solubility of ethyl cellulose and weak bond formation
(Table 3). Hence batches P4 and P5 were eliminated for
further study. Batch P1 containing PVA:PVP shows fast
release of drug (101.26% at 8h) from patch due to burst
eﬀect of PVP and also more solubility in water. So batch P1
was also eliminated.
3.2. Folding Endurance, Tensile Strength, % Elongation and
Thickness. The results of folding endurance, tensile strength,
% elongation and thickness of factorial design batches
are shown in Table 4. The folding endurance values of all
the factorial design patches were found satisfactory which
indicates that the patches prepared using PEG 400 in a
concentration of 30%w/w of polymer were having optimum
ﬂexibility and were not brittle. The tensile strength of the
patches prepared with HPMC E15 and PVP were found
in between 0.38 ± 0.015kg/cm2 to 0.63 ± 0.015kg/cm2,
which were 0.45 ± 0.014kg/cm2 to 0.92 ± 0.017kg/cm2 for
the patches composed of HPMC K100 and were 0.53 ±
0.011kg/cm2 to 0.95 ± 0.015kg/cm2 for the patches com-
posed of HPMC K4M. It was observed that with the increase
of PVP concentrations and HPMC grade, the tensile strength
of the patches gradually increased. The % elongation was
f o u n dt ob ei nt h er a n g eo f2 8 .95±0.015% to 41.2±0.015%.
The formulation F8 showed minimum % elongation among
the other entire factorial design batches 28.95 ± 0.015%.
It indicates inverse relation between tensile strength and %
elongation. The thickness ranges were 0.12 ±0.025 to 0.25 ±
0.022mm.Theresultsshowedthatthepatcheswereuniform,
as it was evidenced by SD value, which were less than 0.01 for
all the factorial design batches.
3.3. Moisture Content, Moisture Uptake, and Drug Content
Studies. The moisture content in the patches ranged from
3.24 ± 0.017 to 4.12 ± 0.015%. The moisture content in
the formulations was found to be increased by increase inISRN Pharmaceutics 5
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Figure 1 :I nv i t r od r u gr e l e a s ep r o ﬁ l ef o rb a t c hF 1t oF 9 .
the concentration of PVP K30 and also with increasing the
g r a d eo fH P M C .T h em o i s t u r eu p t a k ei nt h ep a t c h e sr a n g e d
from 5.27 ± 0.012 to 7.89 ± 0.019%. The moisture uptake
was found to be higher in batches F7, F8, and F9, which
might be due to HPMC K4M. The lower moisture content in
the formulations helps them to remain stable and become a
completelydriedandbrittleﬁlm.Again,lowmoistureuptake
protects the material from microbial contamination and
bulkiness. The drug content ranged from 74.282 to 78.98%.
All formulations were acceptable with regard to Repaglinide
content (Table 4).
3.4. In Vitro Drug Release Study. The drug release char-
acteristics of the formulation were studied in in vitro
conditions by using artiﬁcial semipermeable membrane. The
formulation F1–F3 has shown release of about 96.83%,
101.057% at 10h and 98.26% at 9h, respectively. This is
may be due to low viscosity of HPMC E15 LV polymer
which is rapidly soluble than HPMC K4M and HPMC K100.
The formulation F4–F9 has shown release of about 70.02%,
88.49%, 92.343%, 68.01%, 69.014%, and 84.804% at 12th
hour,respectively(Figure 1).HPMCK4Mshowsslowrelease
of drug from patch due to matrix formation and also its
high viscosity which aﬀect the release while HPMC K100
shows predicted release. The order of drug release was found
to be F2>F3>F1>F6>F5>F9>F4>F8>F7. The in vitro release
data of F1 to F7 formulations ﬁtted well into the Zero order
equation, correlation coeﬃcient values were between 0.9869
and 0.9986 while F8 and F9 follows ﬁrst-order release. Hixon
crowell law and Highuchi model was applied to test the
release mechanism. R2 values are higher for Highuchi model
than Hixon crowell for all formulations, hence, drug release
from all batches follow diﬀusion rate-controlled mechanism.
According to Korsmeyer-Peppas model, a value of slope for
F1, F2, F3, F7, and F9 was >0.85, so it indicates that the
release mechanism follows zero order while for F4, F5, F6,
and F8 was between 0.5 to 0.85 which indicates the release
mechanism was non-Fickian diﬀusion (Table 2)[ 15].
3.5.InVitroPermeationStudy. TheformulationF6exhibited
87.4%ofdrugpermeatedin12hwithaﬂuxof8.65μg/cm2/h
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Figure 2: In vitro drug permeation proﬁle for batch F6.
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Figure 3: Response surface plot for tensile strength.
(with a permeation coeﬃcient of 3.967cm/h) (Figure 2).
Plotting the cumulative amounts of drug permeated per
square centimeter of the patches through the rat abdominal
skin against time showed that the permeation proﬁles of
drug might follow zero-order kinetics as it was evident
by correlation coeﬃcients 0.992, better ﬁt than ﬁrst order
(R2 = 0.982) and Higuchi model (R2 = 0.987) (Figure 3).
According to korsmeyer-Peppas model, a value of slope for
F6 was between 0.5 and 0.85 (0.678) which indicates that the
release mechanism was non-Fickian diﬀusion. The results of
drug permeation from transdermal patches of Repaglinide
through the rat abdominal skin conﬁrmed that Repaglinide
was released from the formulation and permeated through
the rat skin and, hence, could possibly permeate through the
human skin.
3.6. Full Factorial Design. A statistical model incorporating
interactive and poly nominal terms was used to evaluate the
responses.
Yi = b0 +b1X1 +b2X2 +b12X1X2 +b11X2
1 +b22X2
2,( 5 )
where Y is the dependent variable, b0 is the arithmetic
mean response of the 9 runs, and bi is the estimated
coeﬃcient for the factor Xi. The main eﬀects (X1 and X2)6 ISRN Pharmaceutics
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represent the average result of changing 1 factor at a time
from its low to high values. The two way interaction terms
(X12) show how the response changes when two factors are
simultaneously changed. Polynomial terms (X11 and X22)
are included to investigate nonlinearity. The in vitro release
proﬁle for 9 batches showed a variation (i.e., tensile strength,
% cumulative drug release at 1h (Q1), % cumulative drug
release at 9h (Q9), and diﬀusion coeﬃcient). The data
indicate that the release proﬁle of the drug is strongly
dependent on the selected independent variables. The ﬁtted
equations (full and reduced) relating the responses, tensile
strength, Q1, Q9, and diﬀusion coeﬃcient to the transformed
factorareshowninTable 5.Thepolynomialequationscanbe
used to draw conclusions after considering the magnitude of
coeﬃcient and the mathematical sign it carries (i.e., negative
or positive). Table 6 shows the results of analysis of variance
(ANOVA), which was performed to identify insigniﬁcant
factors. Data were analyzed using Microsoft Excel.
R2 value for tensile strength, Q1, Q9, and diﬀusion
coeﬃcient are 0.9431, 0.9318, 0.9648, and 0.8030, respec-
tively, indicating good correlation between dependent and
independent variables. The reduced models were developed
for response variables by omitting the insigniﬁcant terms
with P>0.05. The terms with P<0.05 were considered
statistically signiﬁcance and retained in the reduced model.
The coeﬃcients for full and reduced models for response
variables are shown in Table 5.
3.7. Full and Reduced Model for Tensile Strength. The signif-
icance levels of the coeﬃcients b12, b2
1 and b2
2 were found
to be P = 0.3833, 0.7763, and 0.7959, respectively; hence,
they were omitted from the full model to generate a reduced
model. The results of statistical analysis are shown in Table 5.
The coeﬃcients b1 and b2 were found to be signiﬁcant at
P< 0.05; hence, they were retained in the reduced model.
The reduced model was tested in proportion to determine
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0.6
0.7
0.8
0.9
1.1
D
i
ﬀ
u
s
i
o
n
c
o
e
ﬃ
c
i
e
n
t
B: PVP concentration.
1
1
1
0.5
0.5 0
0
−0.5
−0.5
−1
−1
A: Grade of HPMC
Figure 6: Response surface plot for diﬀusion coeﬃcient.
whether the coeﬃcients b12, b2
1,a n db2
2 contribute signiﬁcant
information to the prediction of tensile strength. The results
of model testing are shown in Table 6. The critical value of F
for α = 0.05 is equal to 9.27 (df = 3,3). Since the calculated
value (F = 0.404) is less than critical value (F = 9.27), it may
be concluded that the terms b12, b2
1,a n db2
2 do not contribute
signiﬁcantly to the prediction of tensile strength and can be
omitted from the full model to generate the reduced model.
3.8. Full and Reduced Model for Q1. The signiﬁcance levels of
the coeﬃcients b1, b2, b12 and b2
2 were found to be P = 0.129,
0.064, 0.962, and 0.658, respectively, so they were omitted
from the full model to generate a reduced model. The results
of statistical analysis are shown in Table 5. The coeﬃcientISRN Pharmaceutics 7
Table 5: Summary of results of regression analysis.
Tensile strength
Response b0 b1 b2 b12 b2
1 b2
2 (tensile strength)
FM 0.638889 0.141667 0.19 0.0425 −0.01833 0.016667
RM 0.637778 0.141667 0.19 – – –
Q1hr
Response (Q1) b0 b1 b2 b12 b2
1 b2
2
FM 15.05272 −1.25 1.734694 −0.038 −5.53572 0.510204
RM 15.39286 – – – −5.53572 –
Q9hr
Response (Q9) b0 b1 b2 b12 b2
1 b2
2
FM 60.39966 −22.2619 6.649658 −0.041 5.586733 6.517858
RM 68.46939 −22.2619 – – – –
Diﬀusion coeﬃcient
Response b0 b1 b2 b12 b2
1 b2
2 (diﬀusion coeﬃcient)
FM 0.64641 −0.09322 −0.03172 −0.011 0.231885 0.056385
R M – – ––– –
FM: full model, RM: reduce model.
Table 6: Calculation for testing the model in portions.
Tensile strength
DF SS MS FR 2
Regression
FM 5 0.345469 0.069094 9.924378 0.94299 Fcal = 0.4047080856747338
RM 2 0.337017 0.168508 34.46109 0.91992 Ftab = 9.27663
Error
FM 3 0.020886 0.006962 – – DF (3,3)
RM 6 0.029339 0.00489 – –
For Q1
DF SS MS FR 2
Regression
FM 5 89.24479 17.84896 8.196259 0.93179 Fcal = 3.209464
RM 1 61.28835 61.28835 12.43909 0.6399 Ftab = 9.11718
Error
FM 3 6.533088 2.177696 – – DF (4,3)
RM 7 34.48953 4.927076 – –
For Q9
DF SS MS FR 2
Regression
FM 5 3386.258 677.2515 16.42181 0.964751 Fcal = 2.50177555838715
RM 1 2973.555 2973.555 38.80292 0.847171 Ftab = 9.11718
Error
FM 3 123.723 41.24098 – – DF (4,3)
RM 7 536.4257 76.63224 – –
For Diﬀusion coeﬃcient
DF SS MS FR 2
Regression
FM 5 0.172597 0.034519 2.445924 0.80302 Fcal = 3
RM – ––––Ftab = 9.013455168
Error
FM 3 0.042339 0.014113 – – DF (5,3)
RM – ––––
∗DF: degree of freedom; SS: sum of squares; MS: mean of squares; R2: regression coeﬃcient; FM: full model; RM: reduced model.8 ISRN Pharmaceutics
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Figure 7: FTIR spectrum of Repaglinide.
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Figure 8: FTIR spectrum of optimized formulation composition.
b1
1 was found to be signiﬁcant at P< 0.05; hence, it was
retainedinthereducedmodel.Thereducedmodelwastested
inproportiontodeterminewhetherthecoeﬃcientb1,b2,b12,
and b2
2 contribute signiﬁcance information to the prediction
of Q1. The results of model testing are shown in Table 6.T h e
critical value of F for α = 0.05 is equal to 9.11 (df = 4,3).
Since the calculated value (F = 3.209) is less than critical
value (F = 9.11), it may be concluded that the term b1, b2,
b12,a n db2
2 do not contribute signiﬁcantly to the prediction
of Q1 and can be omitted from the full model to generate the
reduced model.
3.9. Full and Reduced Model for Q9. The signiﬁcance levels
of the coeﬃcients b2, b12, b2
1,a n db2
2 were found to be P =
0.0849, 0.9905, 0.3062, and 0.2466, respectively, so they were
omitted from the full model to generate a reduced model.
The results of statistical analysis are shown in Table 5.T h e
coeﬃcient b1 was found to be signiﬁcant at P<0.05; hence,
it was retained in the reduced model. The reduced model
wastestedinproportiontodeterminewhetherthecoeﬃcient
b2, b12, b2
1,a n db2
2 contribute signiﬁcance information to the
prediction of Q9. The results of model testing are shown in
Table 6. The critical value of F for α = 0.05 is equal to 9.11ISRN Pharmaceutics 9
(df = 4,3). Since the calculated value (F = 2.50) is less
than critical value (F = 9.11), it may be concluded that the
term b2, b12, b2
1 and b2
2 do not contribute signiﬁcantly to the
prediction of Q9 and can be omitted from the full model to
generate the reduced model.
3.10. Full and Reduced Model for Diﬀusion Coeﬃcient. The
resultsofstatisticalanalysisareshowninTable 5.Noneofthe
coeﬃcients were found to be signiﬁcant at P< 0.05; hence,
reduced model was not obtained. So diﬀusion coeﬃcient
gives no signiﬁcance eﬀect. The results of model testing are
shown in Table 6. The critical value of F for α = 0.05 is equal
to 9.11 (df = 4,3). Since the calculated value (F = 3.09) is
less than critical value (F = 9.11), it may be concluded that
all the terms do not contribute signiﬁcantly to the prediction
of diﬀusion coeﬃcient.
To demonstrate graphically the eﬀect of grade of HPMC
and concentration of PVP K30, the response surface plots
were generated by using Design expert 8.0.2 trial version
software for the dependent variables tensile strength, Q1, Q9
(% drug release after 1, and 9hours, resp.), and diﬀusion
coeﬃcient (n) shown in Figures 3–6,r e s p e c t i v e l y .
3.11. Comparison of In Vitro Release Proﬁle for Selection
of Optimum Batch. Dissolution proﬁles of all batches of
factorial design were compared with theoretical dissolution
proﬁle. The values of similarity factor (f2) for batches F1 to
F9 are shown in Table 4. Batch F6 showed highest f2 value
(69.187) among all the batches. Hence, batch F6 is more
similar compared to other batches so it was selected as an
optimum batch.
3.12. Drug Excipients Compatibility Study. Drug-excipients
interactions play a vital role in the release of drug from
formulation. The pure Repaglinide and its mixture with dif-
ferent grade of HPMC and PVP K30 were mixed separately
with IR grade KBr and were scanned over a range of 400–
4500 cm−1 using FTIR instrument (FTIR-1700, Shimadzu,
Kyoto, Japan). The drug exhibits peaks due to ketonic group,
alcohol group, secondary amine, terminal CH3 group, and
C=O stretching in COOH and CONH. It was observed that
main peaks of Repaglinide were present in mixture of drug
and polymer, and no change in main peaks of the drug IR
spectra in a mixture of drug and polymers was found. The
FTIR study revealed no physical or chemical interactions
of Repaglinide with each grade of HPMC and PVP K30 as
evident from Figures 7 and 8.
4. Conclusion
The prepared transdermal drug delivery system of Repaglin-
ide using diﬀerent grades of HPMC and PVP K30 had shown
good promising results for all the evaluated parameters. It
was concluded that HPMC K100 and PVP K30 of moderate
level useful for preparation of sustained release matrix
transdermal patch formulation.
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